Medication info
Sitaelmet XR Sustained Release Tablet 100/1000 mg (Sitagliptin, Metformin)

Sitaelmet XR Sustained Release Tablet 100/1000 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
GL Pharma Co., Ltd.
Appearance
Bright blue, oval-shaped, convex, sustained-release film-coated tablet
Packaging
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202201878 · Approved 2022.05.09 · Insurance code 653806160

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving treatment with metformin: For patients with no previous experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving treatment with metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at their current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should take into account the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
GL Pharma Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps effectively control blood sugar in patients with type 2 diabetes by using both sitagliptin and metformin. Managing blood sugar becomes smoother when combined with diet and exercise. This improved blood sugar control aids in diabetes management.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving treatment with metformin: For patients with no previous experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving treatment with metformin: - The recommended initial total daily dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at their current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablet once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should take into account the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains two components, sitagliptin and metformin, primarily used for blood sugar control in patients with type 2 diabetes. Firstly, sitagliptin can cause rare but serious allergic reactions, including anaphylaxis, angioedema, and Stevens-Johnson syndrome, which can severely damage the skin. If any of these symptoms occur, immediately discontinue the medication and consult a physician. Additionally, sitagliptin can cause inflammation of the pancreas, known as acute pancreatitis, so if symptoms such as abdominal pain or vomiting occur, notify medical staff immediately. Metformin can cause lactate acidosis, a rare but life-threatening metabolic complication. Lactate acidosis occurs when there is excessive buildup of lactate in the body, leading to acidosis, with symptoms including malaise, muscle pain, difficulty breathing, and abdominal pain. If these symptoms appear, immediately discontinue medication and go to a hospital. This medication is not to be administered to patients with significantly decreased kidney function, dehydration, severe infections, heart failure, acute myocardial infarction, sepsis, or other serious health conditions. Furthermore, the administration of this medication should be temporarily halted before and after examinations using radiopaque agents, and should only be resumed once kidney function is confirmed to be normal. Pregnant women, women who may become pregnant, nursing mothers, and children under 18 years old should not use this medication. During treatment, symptoms of hypoglycemia may occur, so particularly when used with other antidiabetic medications such as insulin or sulfonylureas, careful monitoring of blood sugar changes is essential. This medication may pose risks for patients with impaired liver function or those who consume excessive alcohol; therefore, caution is needed. Regular check-ups for kidney function and blood tests are necessary during treatment, and Vitamin B12 levels should also be monitored periodically. Patients scheduled for surgery should suspend the medication 48 hours before the procedure, and resume it only after confirming that kidney function has returned to normal post-surgery. Finally, any unusual symptoms such as sudden skin rashes, blisters, severe joint pain, or muscle pain should be reported to a physician immediately.

Side effects

  • Hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
Show 21 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • rash
  • urticaria
  • cutaneous vasculitis
  • elevated liver enzyme levels
  • acute renal failure
  • hypoglycemia
  • peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture and kept at room temperature between 1 and 30 degrees Celsius. By following these storage guidelines, the medication's effectiveness can be maintained for a longer period.

Appearance and packaging

Appearance

Bright blue, oval-shaped, convex, sustained-release film-coated tablet

Package unit

28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.